Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Multi Asset Allocation median (36 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 18 Dec 2008 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI Multi Asset Allocation Fund |
|---|---|
| 18 Dec 2008 | ₹100.00 |
| 09 Jun 2010 | ₹133.66 |
| 29 Nov 2011 | ₹143.47 |
| 20 May 2013 | ₹156.08 |
| 08 Nov 2014 | ₹196.85 |
| 29 Apr 2016 | ₹165.72 |
| 19 Oct 2017 | ₹184.67 |
| 10 Apr 2019 | ₹175.46 |
| 29 Sep 2020 | ₹171.55 |
| 21 Mar 2022 | ₹195.29 |
| 09 Sep 2023 | ₹218.27 |
| 28 Feb 2025 | ₹261.45 |
| 20 Aug 2026 | ₹296.61 |
| Metric | UTI · Regular · IDCW NAV ₹29.96 High risk ★★☆☆☆ | Category median Multi Asset Allocation · 36 funds |
|---|---|---|
| +3.76% | +11.14% | |
| +12.08% | +12.69% | |
| +8.69% | +12.02% | |
| +5.13% | +7.13% | |
| +6.35% | +11.02% | |
| +9.27% | — | |
| +4.84% | +6.44% | |
| +4.04% | +5.23% | |
| +3.19% | +4.49% | |
| Risk | ||
| 9.88% | 10.21% | |
| 0.56 | 0.57 | |
| 0.76 | 0.78 | |
| -37.29% | -13.33% | |
| Nifty 50 | — | |
| +3.60% | +6.86% | |
| 0.72 | 0.63 | |
| 83.8% | 79.6% | |
| 51.6% | 33.7% | |
| 1.82% | 2.10% | |
| ₹6,867Cr | ₹2,835Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 347% | 50% | |
| Sharwan Kumar Goyal | — | |
| 18 Dec 2008 | — | |
| 91 | — | |
| 23.6% | — | |
| 4.6% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.